Критерии оценки качества медицинской помощи
| N | Критерии качества | Оценка выполнена |
| 1 | Выполнен осмотр врачом-онкологом/врачом-хирургом | Да/Нет |
| 2 | Выполнение патолого-анатомическое исследование биопсийного (операционного) материала, с указанием параметров в соответствии с рекомендациями до и\или после оперативного вмешательства (по показаниям) | Да/Нет |
| 3 | Выполнены назначения на определение статуса генов C-KIT, PDGFRA | Да/Нет |
| 4 | Выполнены назначения обследования перед хирургическим лечением в соответствии с рекомендациями | Да/Нет |
| 5 | Выполнено хирургического лечения в объеме, соответствующем указанному в рекомендациях | Да/Нет |
| 6 | Отсутствуют осложнения в раннем послеоперационном периоде (у пациентов, кому выполнено хирургическое лечение) | Да/Нет |
| 7 | Выполнена химиотерапии (по показаниям) | Да/Нет |
| 8 | Проведена реабилитация (по показаниям) | Да/Нет |
"Клинические рекомендации "Гастроинтестинальные стромальные опухоли" (утв. Минздравом России )
Список литературы
1. Hirota S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577 - 580.
2. Miettinen M., Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003; 54: 3 - 24.
3. Архири П.П., Цымжитова Н.Ц., Стилиди И.С. и др. Клиническое и прогностическое значение мутационного статуса у больных гастроинтестинальными стромальными опухолями. Саркомы костей, мягких тканей и опухоли кожи 2013; 1: 42 - 46.
|
|
|
4. Arhiri P., Stilidi I.S., Poddubnaya I., Nikulin M.P., Tsymzhitova N., Mazurenko N.N. Clinical significance of mutational status in gastrointestinal stromal tumors (GIST). J Clin Oncol 2012; 30 (suppl; abstr20501).
5. Corless C.L., Barnett C.M., Heinrich M.C. Gastrointestinal stromal tumours: Origin and molecular oncology. Nature Reviews Cancer 2011; 11(12): 865 - 878.
6. Corless C.L., Fletcher J.A., Heinrich M.C. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813 - 3825.
7. Corless C.L., Barnett C.M., Heinrich M.C. Gastrointestinal stromal tumours: origin and molecular oncology. Nature Reviews Cancer, 2011. DOI: 10.1038/nrc3143.
8. Lasota J. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Miettinen M. Semin Diagn Pathol 2006; 23: 91 - 1.
9. Никулин М.П., Стилиди И.С. Гастроинтестинальные стромальные опухоли (ГИСО). Эпидемиология, диагностика, современные подходы к лечению. Современная онкология Экстра-выпуск 2007: 3 - 50.
10. Heikki J. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human pathology 2008; 39: 1411 - 1419.
11. Agaimy A. Minute, Wunsch P.H., Hofstaedter F. Gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31: 113 - 120.
12. Никулин М.П., Архири П.П., Владимирова Л.Ю., Жабина А.С., Мещеряков А.А., Носов Д.А., Стилиди И.С., Филоненко Д.А. Практические рекомендации по лечению гастроинтестинальных стромальных опухолей. Злокачественные опухоли 2019; 9 No3s2: 2019: 477 - 485.
13. Miettinen M., Lasota J. Gastrointestinal Stromal Tumors. Review on Morphology, Molecular Pathology, Prognosis, and Differential Diagnosis. Arch Pathol Lab Med 2006; 130: 1466 - 1476.
|
|
|
14. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8 Suppl 2: S1.
15. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 1999; 35: 1773.
16. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53: 245 - 266.
17. Joensuu H, Vehtari A, Riihimaki J et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265 - 274.
18. Gold JS, Gonen M, 
A et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045 - 1052.
19. Стилиди И.С., Архири П.П., Никулин М.П. Хирургическое лечение больных с первичными локализованными и местнораспространенными гастроинтестинальными стромальными опухолями. Вестник РОНЦ им. Н.Н. Блохина РАМН 2010; 21(1): 77 - 82.
20. Ohtani H, Maeda K, Noda E et al. Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor. Anticancer Res 2013; 33: 5031 - 5041.
21. Архири П.П., Стилиди И.С., Поддубная И.В. и др. Эффективность хирургического лечения больных с локализованными стромальными опухолями желудочно-кишечного тракта (ЖКТ). Российский онкологический журнал 2016; 5(21): 233 - 237.
|
|
|
22. Eisenberg B.L., Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11: 465 - 475.
23. Ohtani H, Maeda K, Noda E et al. Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor. Anticancer Res 2013; 33: 5031 - 5041.
24. De Matteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 2000; 231: 51 - 8.
25. Demetri G., Benjamin R., Blanke C. et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. 2007; 5(Suppl 2): S1 - S29.
26. Rutkowski P., Alessandro Gronchi, Peter Hohenberger, Sylvie Bonvalot, Patrick 
, Sebastian Bauer, Elena Fumagalli, Pawel Nyckowski, Buu-Phuc Nguyen, Jan Martijn Kerst, Marco Fiore, Elzbieta Bylina, Mathias Hoiczyk, Annemieke Cats, Paolo G. Casali, Axel Le Cesne, 
Treckmann, Eberhard Stoeckle, Johannes. H.W. de Wilt, Stefan Sleijfer, Ronald Tielen, Winette van der Graaf, Cornelis Verhoef, Frits van Coevorden. Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience. Ann Surg Oncol 2013; 20: 2937 - 2943.
27. Corless C.L., Ballman K.V., Antonescu C. et al. Relation for tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST). Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2010; 28 (15Suppl) Abstract 10006.
28. Joensuu H., Eriksson M., Hatrmann J. et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition 2011; 29 (18Suppl) Abstract LBA1.
29. Rutkowski P, Gronchi A, Hohenberger P et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 2013; 20: 2937 - 2943.
|
|
|
30. Eisenberg BL, Harris J, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99: 42 - 47.
31. Corless CL, Ballman KV, Antonescu CR et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 2014; 32: 1563 - 1570.
32. Blanke C.D., Demetri G.D., von Mehren M. et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26(4): 620 - 5.
33. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, inter-group trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626 - 632.
34. Verweij J., Casali P.G, Zalcberg J. Progression free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127 - 34.
35. Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751 - 1757.
36. Raut C.P., Posner M, Desai J. et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006 May 20; 24; 15: 2325 - 31.
37. Rutkowski P., Nowecki Z., Nyckowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93: 304 - 311.
38. Стилиди И.С., Архири П.П., Никулин М.П.. Хирургическое лечение больных с рецидивными и метастатическими стромальными опухолями желудочно-кишечного тракта. Вопросы онкологии 2011; 4(57): 508 - 512.
39. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28: 1247 - 1253.
40. P. G. Casali, N. Abecassis, S. Bauer, et al. ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (4Suppl): iv68 - iv78.
41. Le Cesne A., Ray-Coquard I., Bui B.N. et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11(10): 942 - 949.
42. Demetri G.D., van Oosterom A.T., Garrett C.R. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329 - 38.
43. George S, Blay JY, Casali PG et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45: 1959 - 1968.
44. Janeway KA, Albritton KH, Van Den Abbeele AD et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 2009; 52: 767 - 771.
45. Mark Fairweather, M.D., Vinod P. Balachandran, M.D., George Z. Li, et al. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated with Tyrosine Kinase Inhibitors: A Two Institutional Analysis. Ann Surg. 2018 August; 268(2): 296 - 302.
46. Demetri G.D., Reichardt P., Kang Y.K. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013 Jan 26; 381(9863): 295 - 302.
47. Kang YK, Ryu MH, Yoo C et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013; 14: 1175 - 1182.
48. Montemurro M, Gelderblom H, Bitz U, et.al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer. 2013 Mar; 49(5): 1027 - 31.
49. Scott M. Schuetze, Vanessa Bolejack, Dafydd G., et all. Association of dasatinib with progression-free survival among patients with advanced gastrointestinal stromal tumors resistant to imatinib. JAMA Oncol. 2 - 19; 4(6): 814.
50. Montemurro M, P, Reichardt P, et.al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. 2009 Sep; 45(13): 2293 - 7.
51. Sawaki A, Nishida T, Doi T, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer. 2011 Oct 15; 117(20): 4633 - 41.
52. Ganjoo KN, Villalobos VM. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2014 Jan; 25(1): 236 - 40.
53. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatment related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2103; 92: 715 - 727.
54. Luther A., Gabriel J., Watson R.P., Francis N.K. The Impact of Total Body Prehabilitation on Post-Operative Outcomes After Major Abdominal Surgery: A Systematic Review. World J Surg 2018 Sep; 42(9): 2781 - 2791.
55. Снеговой А.В., Бесова Н.С., Веселов А.В., Кравцов С.А., Ларионова В.Б., Сельчук В.Ю. и др. Практические рекомендации по нутритивной поддержке у онкологических больных. Злокачественные опухоли 2016; 4 (Спецвыпуск 2): 2 - 450.
56. Arends J., Bachmann P., Baracos V., Barthelemy N., Bertz H., Bozzetti F., Fearon K., 
E., Isenring E., Kaasa S. et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition 2017; 36: 11 - 48.
57. Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol 2015 Dec; 22(13): 4117 - 23. DOI: 10.1245/s10434-015-4550-z.
58. Hijazia Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. International Journal of Surgery 2017 March; 39: 156 - 162.
59. Gemmill E.H., Humes D.J., Catton J.A. Systematic review of enhanced recovery after gastro-oesophageal cancer surgery. Ann R Coll Surg Engl 2015; 97: 173 - 179.
60. Pisarska M., 
P., Major P., Wysocki M., 
A., 
M. Enhanced recovery after surgery protocol in oesophageal cancer surgery: Systematic review and meta-analysis. PLoSONE 2017; 12(3): e0174382.
61. Feng F., Ji G., Li J.P., Li X.H., Shi H., Zhao Z.W., Wu G.S., Liu X.N., Zhao Q.C. Fast-track surgery could improve postoperative recovery in radical total gastrectomy patients. World J Gastroenterol 2013; 19(23): 3642 - 48.
62. Souza Possaa S., Braga Amador C., Meira Costa A., Takahama Sakamoto E., Seiko Kondoa C., Maida Vasconcellos A.L., Moran de Brito C.M., Pereira Yamaguti W. Implementation of a guideline for physical therapy in the postoperative period of upper abdominal surgery reduces the incidence of atelectasis and length of hospital stay. Revista Portuguesa de Pneumologia 2014; 20(2): 69 - 77.
63. Lewis L.K., Williams M.T., Olds T.S. The active cycle of breathing technique: A systematic review and meta-analysis. Respiratory Medicine 2012; 106(2): 155 - 172.
64. Almeida E.P.M., Almeida J.P., Landoni G., Galas F.R.B.G, Fukushima J.T., Fominskiy E., Brito C.M.M. et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: arandomized controlled trial. British Journal of Anaesthesia 2017; 119(5): 900 - 907.
65. Mitchinson A.R., Kim H.M., Rosenberg J.M., Geisser M., Kirsh M., Cikrit D., Hinshaw D.B. Acute postoperative pain management using massage as an adjuvant therapy. A randomized trial. Archive Surgery 2007; 142(12): 1158 - 1167.
66. Kukimoto Y., Ooe N., Ideguchi N. The Effects of Massage Therapy on Pain and Anxiety after Surgery: A Systematic Review and Meta-Analysis. Pain Manag Nurs 2017; 18(6): 378 - 390.
67. Swarm R.A., Abernethy A.P., Anghelescu D.L., Benedetti C., Buga S., Cleeland C. et al. Adult cancer pain. J Natl Compr Canc Netw 2013; 11(8): 992 - 1022.
68. Cho I., Son Y., Song S., Bae Y.J., Kim Y.N., Kim H.-I., Lee D.T., Hyung W.J. Feasibility and Effects of a Postoperative Recovery Exercise Program Developed Specifically for Gastric Cancer Patients (PREP-GC) Undergoing Minimally Invasive Gastrectomy. J Gastric Cancer 2018; 18(2): 118 - 133.
69. Shin K.Y., Guo Y., Konzen B., Fu J., Yadav R., Bruera E. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011; 90(5): 63 - S68.
70. Bourke L., Homer K.E., Thaha M.A., Steed L., Rosario D.J., Robb K.A. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review. Br J Cancer 2014; 110: 831 - 841.
71. Hunter E.G., Baltisberger J. Functional outcomes by age for inpatient cancer rehabilitation: a retrospective chart review. J Appl Gerontol 2013; 32(4): 443 - 456.
72. Грушина Т.И. Реабилитация в онкологии: физиотерапия. М.: ГЭОТАР-Медиа; 2006. 240 с.
73. Hu C., Zhang H., Wu W. et al. Acupuncture for Pain Management in Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2016: 1720239.
74. O'Neill L.M., Guinan E., Doyle S.L., Bennett A.E., Murphy C., Elliott J.A., O'Sullivan J., Reynolds J.V., Hussey J. The RESTORE Randomized Controlled Trial Impact of a Multidisciplinary Rehabilitative Program on Cardiorespiratory Fitness in Esophagogastric cancer Survivorship. AnnSurg 2018; 268: 747 - 755.
75. Ajani J.A., D"Amico T.A., Almhanna K., Bentrem D.J., Chao J., Das P., Denlinger C.S., Fanta P., Farjah F., Fuchs C.S., Gerdes H. et al. Gastric Cancer. Version 3. 2016, NCCN Clinical Practice Guidelines in Oncology. JNatlComprCancNetw 2016 Oct; 14(10): 1286 - 1312.
76. Kripp M., 
A.L., Belle S., Gerhardt A., Merx K., Hofmann W.K., Hofheinz R.D. Does physical activity improve quality of life in cancer patients undergoing chemotherapy? Oncol Res Treat 2015; 38(5): 230 - 6.
77. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3: 961 - 968.
78. Bland K.A., Zadravec K., Landry T., Weller S., Meyers L., Campbell K.L. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Critical Reviews in Oncology/Hematology 2019 April; 136: 79 - 85.
79. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26: 1019 - 1028.
80. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44: 1289 - 1304.
81. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018 Dec; 10(Suppl35): S4391 - S4399.
82. Kinkead B., Schettler P.J., Larson E.R., Carroll D., Sharenko M., Nettles J., Edwards S.A., Miller A.H., Torres M.A., Dunlop B.W., Rakofsky J.J., Rapaport M.H. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer 2018 Feb 1; 124(3): 546 - 554.
83. Lee J.M., Look R.M., Turner C., Gardiner S.K, Wagie T., Douglas J., Sorenson L., Evans, Kirchner S., Dashkoff C., Garrett K., Johnson N. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 2012 May 30; 5suppl: 9019 - 9019.
84. Rick O., von Hehn U., Mikus E., Dertinger H., Geiger G. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2016; 38(2): 85 - 94.
85. 
M., 
A., Yildirim S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014 May; 46(5): 454 - 60.
86. Oberoi S., Zamperlini-Netto G., Beyene J., Treister N.S., Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. Send to PLoS One 2014 Sep 8; 9(9): e107418.
87. Guo W.C., Wang F. Effect of nerve electrical stimulation for treating chemotherapy-induced nausea and vomiting in patients with advanced gastric cancer: A randomized controlled trial. Medicine (Baltimore) 2018; 97(51): e13620.
88. Ross M., Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs 2017 (1); 21(2): 226 - 233.
89. D'Ambrosio L, Palesandro E, Boccone P et al. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. Eur JCancer 2017; 78: 122 - 132.
Дата добавления: 2021-02-10; просмотров: 65; Мы поможем в написании вашей работы! |
Мы поможем в написании ваших работ!